Belite Bio's Q1 net loss widens on higher R&D costs

Belite Bio

20/05/2026 11:10

Overview

US retinal drug developer posts bigger than expected Q1 GAAP loss per share

Net loss widened yr/yr as operating expenses rose on R&D and commercialization costs

Result Drivers

R&D SPENDING - Higher research and development expenses driven by DRAGON II trial costs, manufacturing expenses, and consultant fees

COMMERCIALIZATION PREPARATION - Selling, general and administrative expenses rose due to share-based compensation, professional service fees, and expanded team for commercialization

INTEREST INCOME - Other income increased mainly from interest on bank deposits and U.S. treasury bills and notes

Company press release: ID:nGNXsFQPg

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q1 Adjusted EPS
-$0.34
Q1 EPS
Miss
-$0.68
-$0.64 (7 Analysts)
Q1 Net Income
-$26.94 mln
Q1 Income From Operations
-$32.68 mln


Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the biotechnology & medical research peer group is "buy"

Wall Street's median 12-month price target for Belite Bio Inc is $200.50, about 43.5% above its May 19 closing price of $139.70

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)